Analysis of Several Pathways for Efficient Killing of Prostate Cancer Stem Cells: A Central Role of NF-κB RELA

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Immunotherapy

Background:

• Prostate cancer remains a significant global health concern.
• Cancer stem cells (CSCs) drive tumor growth and treatment resistance.
• Identifying CSC vulnerabilities is crucial for effective therapies.

Purpose of the Study:

• To characterize prostate cancer stem cells (PCSCs) and investigate their response to immunotherapeutic strategies.
• To explore the role of NF-κB signaling in PCSC survival and sensitivity to cell death induction.
• To identify potential targets for personalized treatment of prostate cancer.

Main Methods:

• Isolation and characterization of PCSCs from patient adenocarcinomas.
• Analysis of stem cell and cancer marker expression (e.g., TWIST, EPCAM, SNAIL, SLUG, CD44, CD133).
• Assessment of aldehyde dehydrogenase (ALDH) activity and programmed cell death 1 (PD-1) ligand expression.
• Evaluation of immunotherapeutic agents, including PD-1 inhibitors and interferon gamma signaling.
• Investigation of NF-κB signaling pathways and response to tumor necrosis factor (TNF).

Main Results:

• PCSCs expressed key stem cell markers and had a significant ALDH-positive fraction.
• Standard immunotherapies (PD-1 inhibition) and interferon gamma signaling showed limited efficacy.
• Two distinct PCSC populations were identified based on NF-κB signaling: one canonical, one blunted.
• PCSCs with blunted NF-κB activation were susceptible to TNF-induced cell death.

Conclusions:

• Prostate CSCs exhibit heterogeneous responses to current immunotherapies.
• NF-κB signaling pathway status is a critical determinant of PCSC sensitivity to TNF.
• Assessing NF-κB induction in PCSCs post-surgery can guide personalized therapeutic strategies, including TNF-based treatments or NF-κB inhibitors.